References
- Drucker B J, Lydon N B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3–7
- Savage D G, Antman K H. Drug therapy: imatinib mesylate–a new oral targeted therapy. N Engl J Med 2002; 346: 683–693
- Peng B, Dutreix C, Mehring G, Hayes M J, Ben-Am M, Seiberling M, et al. Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion. J Clin Pharmacol 2004; 44: 158–162
- Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002; 768: 325–340
- Peng B, Hayes M, Resta D, Racine-Poon A, Drucker B J, Talpez M, et al. Pharmacokinetics and pharmacodynamics of Imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935–942
- Schmidli H, Peng B, Riviere G J, Capdeville R, Hensley M, Gathmann I, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2004; 60: 35–44
- Larson R A, Druker B J, Guilhot F A, O'Brien S G, Riviere G J, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022–4028
- Beumer J H, Natale J J, Lagattuta T F, Raptis A, Eqorin M J. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 2006; 26: 903–907
- Deininger M W, O'Brien S G, Ford J M, Drucker B J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21: 1637–1647
- Cohen M H, Williams G, Johnson J R, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical Cancer Res 2002; 8: 935–942
- Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Res 2002; 8: 3034–3038